Arcoma Inkomsten in het verleden
Verleden criteriumcontroles 6/6
Arcoma has been growing earnings at an average annual rate of 3.5%, while the Medical Equipment industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 6.4% per year. Arcoma's return on equity is 22%, and it has net margins of 7.6%.
Belangrijke informatie
3.5%
Groei van de winst
2.4%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 6.2% |
| Inkomstengroei | 6.4% |
| Rendement op eigen vermogen | 22.0% |
| Nettomarge | 7.6% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business
Aug 22
At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?
Aug 07Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?
Apr 26Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce
Feb 06Is Arcoma (STO:ARCOMA) A Risky Investment?
Jan 15We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt
Sep 11Is Arcoma (STO:ARCOMA) Using Too Much Debt?
Jun 08Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?
Apr 27Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?
Dec 22Is Arcoma (STO:ARCOMA) Using Too Much Debt?
May 03These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively
Oct 28Is Arcoma (STO:ARCOMA) A Risky Investment?
Mar 17Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?
Feb 04Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?
Jan 14
Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 12These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well
Dec 17Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)
Nov 21Opbrengsten en kosten
Hoe Arcoma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 171 | 13 | 44 | 0 |
| 30 Jun 24 | 175 | 13 | 45 | 0 |
| 31 Mar 24 | 172 | 9 | 45 | 0 |
| 31 Dec 23 | 163 | 3 | 45 | 0 |
| 30 Sep 23 | 153 | 0 | 46 | 0 |
| 30 Jun 23 | 146 | 0 | 45 | 0 |
| 31 Mar 23 | 138 | 1 | 44 | 0 |
| 31 Dec 22 | 125 | 2 | 43 | 0 |
| 30 Sep 22 | 105 | -6 | 44 | 0 |
| 30 Jun 22 | 99 | -10 | 44 | 0 |
| 31 Mar 22 | 105 | -11 | 44 | 0 |
| 31 Dec 21 | 117 | -7 | 45 | 0 |
| 30 Sep 21 | 126 | -6 | 45 | 0 |
| 30 Jun 21 | 125 | -2 | 44 | 0 |
| 31 Mar 21 | 121 | -1 | 41 | 0 |
| 31 Dec 20 | 117 | 1 | 38 | 0 |
| 30 Sep 20 | 122 | 8 | 34 | 0 |
| 30 Jun 20 | 130 | 10 | 36 | 0 |
| 31 Mar 20 | 132 | 10 | 38 | 0 |
| 31 Dec 19 | 134 | 7 | 39 | 0 |
| 30 Sep 19 | 133 | 5 | 40 | 0 |
| 30 Jun 19 | 132 | 2 | 40 | 0 |
| 31 Mar 19 | 129 | 1 | 41 | 0 |
| 31 Dec 18 | 119 | -2 | 42 | 0 |
| 30 Sep 18 | 111 | -1 | 42 | 0 |
| 30 Jun 18 | 98 | -6 | 42 | 0 |
| 31 Mar 18 | 94 | -10 | 41 | 0 |
| 31 Dec 17 | 92 | -10 | 40 | 0 |
| 30 Sep 17 | 98 | -9 | 41 | 0 |
| 30 Jun 17 | 108 | -4 | 42 | 0 |
| 31 Mar 17 | 106 | -5 | 45 | 0 |
| 31 Dec 16 | 102 | -12 | 47 | 0 |
| 30 Sep 16 | 106 | -12 | 49 | 0 |
| 30 Jun 16 | 105 | -13 | 48 | 0 |
| 31 Mar 16 | 104 | -15 | 48 | 0 |
| 31 Dec 15 | 123 | -6 | 49 | 0 |
| 30 Sep 15 | 117 | -6 | 47 | 0 |
| 30 Jun 15 | 119 | -5 | 46 | 0 |
| 31 Mar 15 | 133 | 1 | 47 | 0 |
| 31 Dec 14 | 130 | 1 | 45 | 0 |
| 30 Sep 14 | 134 | -7 | 48 | 0 |
| 31 Dec 13 | 108 | -14 | 50 | 0 |
Kwaliteitswinsten: ARCOMA has high quality earnings.
Groeiende winstmarge: ARCOMA's current net profit margins (7.6%) are higher than last year (0.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ARCOMA has become profitable over the past 5 years, growing earnings by 3.5% per year.
Versnelling van de groei: ARCOMA's earnings growth over the past year (4241.1%) exceeds its 5-year average (3.5% per year).
Winst versus industrie: ARCOMA earnings growth over the past year (4241.1%) exceeded the Medical Equipment industry 28.2%.
Rendement op eigen vermogen
Hoge ROE: ARCOMA's Return on Equity (22%) is considered high.